NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2031220177

Registered date:02/07/2022

Survey on the occurrence of heart failure after administration of TARLIGE -MID-NET Cohort Study-

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedNeuropathic pain
Date of first enrollment01/01/2009
Target sample size24000
Countries of recruitment
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeOccurrence of heart failure
Secondary Outcome

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderBoth
Include criteriaPatients who meet all of the following criteria will be enrolled. 1) During the enrollment period (April 15, 2019 to June 30, 2025), there is a prescription date for either mirogabalin, an extract from inflammatory rabbit skin inoculated by vaccinia virus, or pregabalin (hereinafter referred to as the "Target Drug"). Hereinafter, the earliest prescription date among all prescription dates for the target drug during the enrollment period will be defined as the "first prescription date." 2) The date of the earliest medical record after the start date of the data period is at least 366 days prior to the date of the first prescription during the enrollment period.
Exclude criteriaExclude patients who meet any of the following criteria: 1) There is a prescription date for the target drug between 365 days prior to the first prescription date and the day prior to the first prescription date. 2) There are several prescribing dates for the target drug on the first prescription date. 3) Between 180 days prior to the first prescription day and the first prescription day, the BNP value at the measurement day closest to the first prescription day is >100 pg/ml. 4) There is a date of diagnosis of heart failure before the first prescription date. 5) Between 1826 days prior to the first prescription date and the first prescription date, there is a prescription date for chemotherapy or radiation therapy for malignancies. 6) There is a date of dialysis prior to the first prescription date.

Related Information

Contact

Public contact
Name GPSP for Contact
Address 3-5-1,Nihonbashi Honcho,Chuo-ku,Tokyo Tokyo Japan 103-8426
Telephone +81-3-6225-1059
E-mail contact_gpsp@daiichisankyo.co.jp
Affiliation Daiichi Sankyo Co.,Ltd.
Scientific contact
Name Yomei for Matsuoka
Address 3-5-1,Nihonbashi Honcho,Chuo-ku,Tokyo Tokyo Japan 103-8426
Telephone +81-3-6225-1059
E-mail contact_gpsp@daiichisankyo.co.jp
Affiliation Daiichi Sankyo Co.,Ltd.